495 related articles for article (PubMed ID: 27271256)
1. A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease.
Trasino SE; Tang XH; Jessurun J; Gudas LJ
J Mol Med (Berl); 2016 Oct; 94(10):1143-1151. PubMed ID: 27271256
[TBL] [Abstract][Full Text] [Related]
2. A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease.
Tang XH; Melis M; Lu C; Rappa A; Zhang T; Jessurun J; Gross SS; Gudas LJ
J Biol Chem; 2021 Dec; 297(6):101331. PubMed ID: 34688661
[TBL] [Abstract][Full Text] [Related]
3. Effects of AM80 compared to AC261066 in a high fat diet mouse model of liver disease.
Melis M; Tang XH; Trasino SE; Patel VM; Stummer DJ; Jessurun J; Gudas LJ
PLoS One; 2019; 14(1):e0211071. PubMed ID: 30677086
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid receptor β2 agonists restore glycaemic control in diabetes and reduce steatosis.
Trasino SE; Tang XH; Jessurun J; Gudas LJ
Diabetes Obes Metab; 2016 Feb; 18(2):142-51. PubMed ID: 26462866
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease.
Liang D; Chen H; Zhao L; Zhang W; Hu J; Liu Z; Zhong P; Wang W; Wang J; Liang G
Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):133-142. PubMed ID: 29038049
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of Diabetic Nephropathy Using a Retinoic Acid Receptor
Trasino SE; Tang XH; Shevchuk MM; Choi ME; Gudas LJ
J Pharmacol Exp Ther; 2018 Oct; 367(1):82-94. PubMed ID: 30054312
[TBL] [Abstract][Full Text] [Related]
8. A dietary ketone ester mitigates histological outcomes of NAFLD and markers of fibrosis in high-fat diet fed mice.
Moore MP; Cunningham RP; Davis RAH; Deemer SE; Roberts BM; Plaisance EP; Rector RS
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G564-G572. PubMed ID: 33501889
[TBL] [Abstract][Full Text] [Related]
9. Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease.
Li DJ; Liu J; Hua X; Fu H; Huang F; Fei YB; Lu WJ; Shen FM; Wang P
Metabolism; 2018 Feb; 79():52-63. PubMed ID: 29129819
[TBL] [Abstract][Full Text] [Related]
10. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
11. Lipocalin-2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high-fat diet-fed Ob/Ob mice.
Kim KE; Lee J; Shin HJ; Jeong EA; Jang HM; Ahn YJ; An HS; Lee JY; Shin MC; Kim SK; Yoo WG; Kim WH; Roh GS
Hepatology; 2023 Mar; 77(3):888-901. PubMed ID: 35560370
[TBL] [Abstract][Full Text] [Related]
12. Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy.
Valdecantos MP; Ruiz L; Pardo V; Castro-Sanchez L; García-Monzón C; Lanzón B; Rupérez J; Barbas C; Naylor J; Trevaskis JL; Grimsby J; Rondinone CM; Valverde ÁM
Sci Rep; 2018 Nov; 8(1):16461. PubMed ID: 30405191
[TBL] [Abstract][Full Text] [Related]
13. Amlexanox reversed non-alcoholic fatty liver disease through IKKε inhibition of hepatic stellate cell.
He Q; Xia X; Yao K; Zeng J; Wang W; Wu Q; Tang R; Zou X
Life Sci; 2019 Dec; 239():117010. PubMed ID: 31672578
[TBL] [Abstract][Full Text] [Related]
14. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
[TBL] [Abstract][Full Text] [Related]
15. Sirtuin 3 (SIRT3) Regulates α-Smooth Muscle Actin (α-SMA) Production through the Succinate Dehydrogenase-G Protein-coupled Receptor 91 (GPR91) Pathway in Hepatic Stellate Cells.
Li YH; Choi DH; Lee EH; Seo SR; Lee S; Cho EH
J Biol Chem; 2016 May; 291(19):10277-92. PubMed ID: 26912655
[TBL] [Abstract][Full Text] [Related]
16. Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition.
Nguyen G; Park SY; Le CT; Park WS; Choi DH; Cho EH
Biochem Biophys Res Commun; 2018 Jan; 495(4):2649-2656. PubMed ID: 29278707
[TBL] [Abstract][Full Text] [Related]
17. STUB1 increases adiponectin expression by inducing ubiquitination and degradation of NR2F2, thereby reducing hepatic stellate cell activation and alleviating non-alcoholic fatty liver disease.
Mao Z; Zhao J; Cui F; Li Z; Cao J; Zhou J; Hou M; Qian Z
Tissue Cell; 2024 Jun; 88():102345. PubMed ID: 38471267
[TBL] [Abstract][Full Text] [Related]
18. A Retinoic Acid Receptor
Tang XH; Gambardella J; Jankauskas S; Wang X; Santulli G; Gudas LJ; Levi R
J Pharmacol Exp Ther; 2021 Nov; 379(2):182-190. PubMed ID: 34389654
[TBL] [Abstract][Full Text] [Related]
19. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
